Instil Bio Inc. (TIL) - Total Liabilities
Based on the latest financial reports, Instil Bio Inc. (TIL) has total liabilities worth $89.73 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Instil Bio Inc. - Total Liabilities Trend (2019–2025)
This chart illustrates how Instil Bio Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Instil Bio Inc. current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Instil Bio Inc. Competitors by Total Liabilities
The table below lists competitors of Instil Bio Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Theralase Technologies Inc.
V:TLT
|
Canada | CA$1.94 Million |
|
Oneflow AB
ST:ONEF
|
Sweden | Skr131.49 Million |
|
Prestige Wealth Inc.
NASDAQ:AURE
|
USA | $42.54 Million |
|
Shenzhen SEG Co Ltd
SHE:200058
|
China | HK$2.47 Billion |
|
China Bicycle Co Holdings Ltd
SHE:200017
|
China | CN¥93.60 Million |
|
CoAsia Corporation
KQ:045970
|
Korea | ₩246.96 Billion |
|
Euro Sun Mining Inc
TO:ESM
|
Canada | CA$7.09 Million |
|
Daily Polymer
TWO:4716
|
Taiwan | NT$566.25 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Instil Bio Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see TIL market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 39.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Instil Bio Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Instil Bio Inc. (2019–2025)
The table below shows the annual total liabilities of Instil Bio Inc. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $89.66 Million | -4.75% |
| 2024-12-31 | $94.13 Million | -5.68% |
| 2023-12-31 | $99.80 Million | -15.80% |
| 2022-12-31 | $118.52 Million | +116.35% |
| 2021-12-31 | $54.78 Million | +105.61% |
| 2020-12-31 | $26.64 Million | +1776.41% |
| 2019-12-31 | $1.42 Million | -- |
About Instil Bio Inc.
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.